• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Can Oxytocin Decrease Bleeding during Abdominal Myomectomy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • There is conflicting data as to whether oxytocin can reduce bleeding during myomectomy  
  • Atashkhoei et al. (BJOG, 2018) sought to determine the effectiveness and safety of oxytocin for reducing blood loss in abdominal myomectomy

METHODS: 

  • Double-blind randomized controlled trial (RCT) 
    • Participants: Otherwise healthy women who were candidates for abdominal myomectomy 
      • No prior GnRh analogues 
      • No submucous fibroids  
  • Women received either 
    • Oxytocin 30 IU in 500 ml normal saline at a rate of 120 ml/hour starting during myomectomy procedure  
    • Placebo of normal saline 
  • Primary outcome: Intraoperative blood loss (ml)  
    • Calculated by: sum of canisters containing irrigation fluids and suctioned blood minus used irrigation solution plus the amount of absorbed blood in used sponges 
  • Secondary outcomes 
    • Transfusion | Vitals | Hemoglobin and hematocrit | Time to ambulation | Other relevant clinical outcomes  
  • Statistics 
    • To detect a difference of 200 ml in blood loss, approximately y40 patients were required in each group 
    • Power of 0.9 and level of significance of 0.05

RESULTS: 

  • 40 in study (oxytocin) group | 40 in placebo group   
  • Uterine size (P=0.74) 
    • Study group: 14.8±0.25 weeks
    • Placebo group: 15.05±0.62 weeks
  • Estimated intra-operative blood loss was significantly lower in the study group  
    • Study group: 189.5±16.72 (SD) mL 
    • Placebo group: 692.25±89.93 mL 
    • 95% CI, 672.54 to 711.96 mL (P<0.0001) 
  • Blood transfusions were significantly less frequent in the study group  
    • Three (7.5%) women in the study group 
    • 10 (25%) women in the placebo group 
    • 95% CI 15.5-34.5 (P<0.001) 
  • Differences also seen in the following outcomes  
    • Duration of surgery (P=0.01) and anesthesia (P=0.02) 
    • Time to ambulation (P=0.03)  
    • Hospitalization time (P<0.0001) 
  • No major side effects identified in either group

CONCLUSION: 

  • Intra-operative oxytocin infusion reduced blood loss and need for transfusion during abdominal myomectomy 
  • Consistent with literature of approximately 20% of women requiring blood transfusion during abdominal hysterectomy 
    • In this study, 25% of placebo group and 7.5% in blood transfusion group required transfusion  
  • Limitations include 
    • Investigators did not weigh fibroid mass  
    • Minimally invasive surgery is becoming the surgery of choice for fibroids, even when large

Learn More – Primary Sources: 

Effect of oxytocin infusion on reducing the blood loss during abdominal myomectomy: a double-blind randomised controlled trial

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What Uterine-Sparing Treatment for Fibroids Has the Best Outcomes?
Uterine Artery Embolization, Focused Ultrasound, or Hysterectomy for Fibroids?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site